Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non Operating Income (2016 - 2022)

Historic Other Non Operating Income for Enanta Pharmaceuticals (ENTA) over the last 11 years, with Q2 2022 value amounting to $393000.0.

  • Enanta Pharmaceuticals' Other Non Operating Income fell 1047.84% to $393000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was -$782000.0, marking a year-over-year increase of 7863.97%. This contributed to the annual value of -$27000.0 for FY2021, which is 11812.08% down from last year.
  • Enanta Pharmaceuticals' Other Non Operating Income amounted to $393000.0 in Q2 2022, which was down 1047.84% from $255000.0 recorded in Q1 2022.
  • Enanta Pharmaceuticals' 5-year Other Non Operating Income high stood at $2.4 million for Q2 2019, and its period low was -$5.3 million during Q3 2020.
  • Its 5-year average for Other Non Operating Income is $222800.0, with a median of $393000.0 in 2022.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first tumbled by 11515.15% in 2018, then soared by 2405000.0% in 2019.
  • Enanta Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$100000.0 in 2018, then soared by 2176.0% to $2.1 million in 2019, then crashed by 67.39% to $677000.0 in 2020, then crashed by 61.89% to $258000.0 in 2021, then skyrocketed by 52.33% to $393000.0 in 2022.
  • Its Other Non Operating Income was $393000.0 in Q2 2022, compared to $255000.0 in Q1 2022 and $258000.0 in Q4 2021.